JPRN-UMIN000007051已完成未知
Switch to oral hypoglycemic agent therapy from insulin injection - Switch to oral hypoglycemic agent therapy from insulin injection
Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science,0 个研究点目标入组 60 人开始时间: 2012年1月11日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) had hypersensitivity or a contraindication to mitiglinide or sitagliptin; (2) had a history of type 1 diabetes or a history of ketoacidosis; (3) experienced repeated episodes of unexplained hypoglycaemia as defined by FPG or without the symptoms of hypoglycaemia or <60 mg/dl with symptoms of hypoglycaemia; (4) concomitantly suffering from infection and planning to have surgery; (5) treatment with a mitiglinide, and a sitagliptin within 12 weeks before screening; (6) concomitant corticosteroid therapy; (7) poorly controlled diabetes; (8) under dialysis and serum creatinine >2.5 mg/dl in men or >2.0 mg/dl in women; (9) alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) more than 2.5-fold the upper limit of normal; (10) poorly controlled hypertensions or systolic blood pressure>160 mmHg, or diastolic blood pressure>100 mmHg; (11) currently and/or previously suffering from heart failure; (12) severe retinopathy; (13) malignancy on active therapeutic regimen or without complete remission or cure; (14) pregnancy or breast feeding; (15) inadequacy to participate in the study, as assessed by the investigators.
研究者
相似试验
已完成
不适用
Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineISRCTN35210312Okhotsk-kai Hospital (Japan)36
已完成
不适用
Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection (SWITCH-2)Type2 DiabetesJPRN-UMIN000008944Department of Medicine, Shiga University of Medical Science15
已完成
不适用
Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injectioType2 DiabetesJPRN-UMIN000007894Department of Medicine, Shiga University of Medical Science15
招募中
不适用
The effective switch from intensive insulin therapy to the once-daily human GLP-1 analogue liraglutide in patients with fairly well controlled type 2 diabetestype 2 diabetesJPRN-UMIN000005202Department of Diabetes and Endocrinology, Kanto Rosai Hospital20
招募中
不适用
Adequate adjustment from insulin degludec to insulin pump therapy in patient with type 1 diabetestype 1 diabetesJPRN-UMIN000013136Department of Pediatrics Osaka City University Graduate School of Medicine20